CAMAGÜEY.- More than 25 thousand patients have received the Cuban therapeutic vaccine against non-small cell lung cancer Cimavax-EGF, the result of scientific research in the largest of the Antilles, with satisfactory results in people in an advanced stage of the illness.
This is how it transpired last Wednesday at the Clinical Trials Management Workshop held in Camagüey, where doctors and specialists participated with presentations for the development of Medicine in the country, which they plan to add to the use of new clinical studies.
Approved by the regulatory agency since 2008, the drug allows greater survival and improves the quality of life of those who receive its benefits after the first chemotherapy session.
Science doctor Mayra Ramos Suzarte, head of the Clinical Trials Department of the Molecular Immunology Center, explained that the universe in the country is more than 15 thousand people in different phases of tests, while mentioning the ability to reach anyone whoever needs it in the primary health system.
Likewise, she highlighted the impact on the international community of a drug that is in phase four of the clinical trial and that is systematically consolidated throughout the country, one of the bastions of the Cuban social system.
During the conference, Ramos Suzarte referred to the results of the province in the pandemic stage, in which the investigations did not stop and important advances were made in the care of patients who contracted the virus.
In this sense, she praised the achievements with the humanized monoclonal antibody Itolizumab, also in Ciego de Ávila and Las Tunas; as well as with Nimotuzumab, thanks to which more than 6,500 patients treated on the Island with COVID-19, in moderate and severe stages, were saved and prevented inflammation caused by the disease, in addition to being used for the treatment of persistent or recurrent cervical cancer, among other pathologies”.
Based on these investigations, the scientific center is now working on a new clinical trial with Itolizumab and Nimotuzumab; and "for this and many other reasons it is a pride and an honor to share with researchers and health professionals in this Workshop where we share experiences and knowledge."
By the way, the expert commented on some of the clinical trials in which the Center for Molecular Immunology is engaged, several of which have already been completed and others with molecules in phase one for the treatment of cancer of different origins.
She highlighted the work with a new molecule called NeuroEpo, which has gained ground in the approach to neurodegenerative diseases and is included in procedures against mild and moderate Alzheimer's, a condition in which the province has a high incidence.
Among the strategies for the coming months, she mentioned the 30 clinical trials conducted by the Molecular Immunology Center in Cuba, of which Camagüey participates in eight and they plan to increase the presence of Camagüey in another seven that are in more advanced stages.
Translated by Linet Acuña Quilez